SG11201807279QA - Binding proteins and methods of use thereof - Google Patents
Binding proteins and methods of use thereofInfo
- Publication number
- SG11201807279QA SG11201807279QA SG11201807279QA SG11201807279QA SG11201807279QA SG 11201807279Q A SG11201807279Q A SG 11201807279QA SG 11201807279Q A SG11201807279Q A SG 11201807279QA SG 11201807279Q A SG11201807279Q A SG 11201807279QA SG 11201807279Q A SG11201807279Q A SG 11201807279QA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- san francisco
- boulevard
- kfkwnlt
- south san
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property ' Organization 11111111011110111010101111101011111011101011111011101111001101111101111011111 International Bureau (10) International Publication Number (43) International Publication Date ..... .......•:;.1 WO 2017/172260 Al 5 October 2017 (05.10.2017) WIP0 I PCT (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 39/395 (2006.01) CO7K 14/475 (2006.01) kind of national protection available): AE, AG, AL, AM, C07K 16/18 (2006.01) C12Q 1/68 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, (21) International Application Number: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US2017/020654 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, (22) International Filing Date: KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, 3 March 2017 (03.03.2017) MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (25) Filing Language: English RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, (26) Publication Language: English TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 62/316,516 31 March 2016 (31.03.2016) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant: NGM BIOPARMACEUTICALS, INC. GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, [US/US]; 333 Oyster Point Boulevard, South San Fran- TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, cisco, CA 94080 (US). TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (72) Inventors: SHEN, Wenyan; 333 Oyster Point Boulevard DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, South San Francisco, CA 94080 (US). TANG, Jie; 333 LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, Oyster Point Boulevard, South San Francisco, CA 94080 SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, (US). WANG, Yan; 333 Oyster Point Boulevard, South GW, KM, ML, MR, NE, SN, TD, TG). San Francisco, CA 94080 (US). MATERN, Hugo; 333 Published: Oyster Point Boulevard, South San Francisco, CA 94080 (US) — with international search report (Art. 21(3)) (74) — with sequence listing part of description (Rule 5.2(a)) Agents: McNICHOLAS, Janet, M. et al.; Jones Day, 250 Vesey Street, New York, NY 10281-1047 (US). (54) Title: BINDING PROTEINS AND METHODS OF USE THEREOF FIG. 1 Human -MIVFI FLAMGLSLENEYTSQTNNCTYLREQCLRDANGCKHAWRVMEDACNDSDPGDPCK Chimpanzee -MIVFIFIAMGLSLENEYTSQTNNCTYLREQCLADANGCKHAWRVMEDACNDSDPGDPCK Cynomolgus -FVVVVI QALGLSLENEYTSQTNNCTYLREQCLHDANGCKHAWRIMEDACNDSDPGDPCK Giant Panda -MVVFI FLAVALCLENESTSETIDCTYLREQCLRDANGCKHAWRIMEDSCNVSEPGNPCK Dog -MIVFIFLAMVLCLENESTSQTIDCTHLREQCLSDADGCKHAWRIMEYSCNVSVPGNPCK Cat -SVLIVI SAMVLCLENESTSQTIDCTYLREQCLSDTNGCKLAWRKMEDSCNVSDPGNPCK Pig - SVIAVLQAVGLYLENESTSQTTDCTYLRELCLNDTDGCKQAWRIMEDACNVSDPGNTCQ Bovine -PLIVVIQAVGLCLN-KSASQTTDCTYLRELCLSDADGCKHAWRIMEDACNVS--GNTCQ Mouse -MLVFIFLAVTLSSENESSSQTNDCAHLIQKCLIDANGCEQSWRSMEDTCLT--PGDSCK Rat -MLVFIFIAVRLSSENESSSQTNDCAYFMRQCLTDTDGCKQSWRSMEDACLV--SGDSCK Chinese Hamster Platypus MKHYFLEVVIALGEKCESASLTTGCLHLRKQCVSAMDGCESAWAVIEDVCNVS--GIENCT * ** * * * * * Human MRNSSYCNLSIQYLVESNFQFKECLCTDDFYCTVNKLLGKKCINKSDNVKED-KFKWNLT Chimpanzee MRNSSYCNLSIQYLVESNFQFKECLCTDDFYCTVNKLLGKKCINKSDNVKED-KFKWNLT Cynomolgus MNNSSYCNLSIOYLVESNERFKECLCTDDFYCTVNKLLGKECVNKSDNMRED-KFKWNLT 11 Giant Panda MKDSSKCNLSIQSLVESNFQFEDCLCTDNLYCTINKLLGEQCINESGNVKEDNQSKWNLT Dog MKDSSNCNLSIQSLVENNFQFEDCLCTDNIYCTINKLLGEQCMNESDNMKEDNQYKWNLT Cat MKDSSNCNLSIQSLVENNFQFEDCLCTGNLHCTINKLLGKKCINESDNMKEDNQSKWNLT Pig MKDSSSCNQSIQSLAESNFQFKDCLCSDDLYCTVNNLIGKKCTNESDNMKEDGVFKRNLT C:= Bovine MKNSSSCGLSIQSLVESNLQFKDCLCFDDLYCTFNKLLGKKCINESDNIKEDNKYKWNLT V::, N Mouse Rat INNSLHCNLSIQALVEKNFQFKECLCMDDLHCTVNKLFGKKCTNKTDNMEKDNKDKWNLT INNPLPCNLSIQSLVEKBFQFKGCLCTDDLHCTVNKIFGKKCTNKTDSMKKDNKYKRNLT Chinese Hamster N Platypus MKESLNCNLSIQLLADRYPAFKDCLCAEDISCSATNFLGRKCIIKTENEHKDKNIKSLWN IN * *** * * *** r * * 11 ..„.... IN 1-1 (57) : The present disclosure provides binding proteins, such as antibodies, that bind to a GDNF Family Receptor Alpha 0 Like el (GFRAL) protein, including human GFRAL protein, and methods of their use. 0
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662316516P | 2016-03-31 | 2016-03-31 | |
| PCT/US2017/020654 WO2017172260A1 (en) | 2016-03-31 | 2017-03-03 | Binding proteins and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201807279QA true SG11201807279QA (en) | 2018-09-27 |
Family
ID=59966343
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201807279QA SG11201807279QA (en) | 2016-03-31 | 2017-03-03 | Binding proteins and methods of use thereof |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US10174119B2 (en) |
| EP (1) | EP3436068A4 (en) |
| JP (2) | JP7021099B2 (en) |
| KR (2) | KR102370762B1 (en) |
| CN (1) | CN109715206B (en) |
| AU (2) | AU2017241161B2 (en) |
| BR (1) | BR112018068898A2 (en) |
| CA (1) | CA3016035A1 (en) |
| CL (1) | CL2018002687A1 (en) |
| CO (1) | CO2018009995A2 (en) |
| IL (1) | IL261666A (en) |
| MX (1) | MX2018011503A (en) |
| MY (1) | MY194669A (en) |
| NZ (1) | NZ745635A (en) |
| PE (1) | PE20190126A1 (en) |
| PH (1) | PH12018501882A1 (en) |
| SG (1) | SG11201807279QA (en) |
| TW (1) | TWI815793B (en) |
| WO (1) | WO2017172260A1 (en) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI815793B (en) * | 2016-03-31 | 2023-09-21 | 美商恩格姆生物製藥公司 | Binding proteins and methods of use thereof |
| US20190234935A1 (en) * | 2016-10-12 | 2019-08-01 | Janssen Biotech, Inc. | Methods for screening for modulators of gdf15-like biological activity |
| CN112543869A (en) * | 2018-08-10 | 2021-03-23 | 诺华股份有限公司 | GFRAL extracellular domains and methods of use |
| US20220127316A1 (en) * | 2019-02-05 | 2022-04-28 | The Trustees Of The University Of Pennsylvania | Peptide Ligands of the Gdnf Family Receptor A-Like (Gfral) Receptor |
| US20220213187A1 (en) * | 2019-05-08 | 2022-07-07 | Agilvax Inc. | Compositions and methods related to xct antibodies |
| US20220296707A1 (en) * | 2019-06-04 | 2022-09-22 | Regents Of The University Of Minnesota | Anti-opioid compounds and methods of making and using same |
| US20220332805A1 (en) * | 2019-09-11 | 2022-10-20 | University Of Cincinnati | Treatment of Skin Blistering Diseases Using Antibodies |
| KR20210150981A (en) | 2020-06-04 | 2021-12-13 | 재단법인대구경북과학기술원 | GFRAL antagonist antibody and use thereof |
| CN115698073A (en) * | 2020-06-04 | 2023-02-03 | 大邱庆北科学技术院 | GFRAL antagonistic antibody and use thereof |
| US20240124606A1 (en) * | 2021-02-22 | 2024-04-18 | Northwestern University | Anti-cd73 monoclonal antibodies |
| WO2022207785A1 (en) * | 2021-03-31 | 2022-10-06 | Kymab Limited | Antibodies to gfral |
| CA3215737A1 (en) | 2021-03-31 | 2022-10-06 | Cambridge Enterprise Limited | Therapeutic inhibitors of gdf15 signalling |
| TW202317630A (en) * | 2021-06-30 | 2023-05-01 | 大陸商上海津曼特生物科技有限公司 | Anti-gfral antibodies and use thereof |
| CA3228576A1 (en) | 2021-08-10 | 2023-02-16 | Byomass Inc. | Anti-gdf15 antibodies, compositions and uses thereof |
| WO2023039359A1 (en) | 2021-09-10 | 2023-03-16 | Ngm Biopharmaceuticals, Inc. | Methods of treating cancer and tumor-related weight loss and cachexia |
| KR20230044121A (en) | 2021-09-24 | 2023-04-03 | 재단법인대구경북과학기술원 | GFRAL antagonist antibody with improved affinity and use thereof |
| WO2023048425A1 (en) * | 2021-09-24 | 2023-03-30 | 재단법인대구경북과학기술원 | Gfral-antagonistic antibody having improved affinity, and use thereof |
| WO2023122213A1 (en) | 2021-12-22 | 2023-06-29 | Byomass Inc. | Targeting gdf15-gfral pathway cross-reference to related applications |
| WO2023150677A2 (en) * | 2022-02-03 | 2023-08-10 | Igm Biosciences, Inc. | Anti-cd38 binding molecules and uses thereof |
| WO2023154953A1 (en) | 2022-02-14 | 2023-08-17 | Ngm Biopharmaceuticals, Inc. | Gdf15 polypeptides for treating and preventing autoimmune diseases |
| WO2023192798A2 (en) * | 2022-03-28 | 2023-10-05 | Coherus Biosciences, Inc. | Anti-ilt4 compositions and methods |
Family Cites Families (123)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5194596A (en) | 1989-07-27 | 1993-03-16 | California Biotechnology Inc. | Production of vascular endothelial cell growth factor |
| FR2650598B1 (en) | 1989-08-03 | 1994-06-03 | Rhone Poulenc Sante | DERIVATIVES OF ALBUMIN WITH THERAPEUTIC FUNCTION |
| US5350836A (en) | 1989-10-12 | 1994-09-27 | Ohio University | Growth hormone antagonists |
| FR2686899B1 (en) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
| WO1994003599A1 (en) | 1992-08-04 | 1994-02-17 | Sagami Chemical Research Center | HUMAN cDNA AND PROTEIN WHICH SAID cDNA CODES FOR |
| US6180602B1 (en) | 1992-08-04 | 2001-01-30 | Sagami Chemical Research Center | Human novel cDNA, TGF-beta superfamily protein encoded thereby and the use of immunosuppressive agent |
| JPH07258293A (en) | 1994-03-23 | 1995-10-09 | Asahi Chem Ind Co Ltd | New protein and its production |
| WO1996018730A1 (en) | 1994-12-15 | 1996-06-20 | Human Genome Sciences, Inc. | Prostatic growth factor |
| US6521227B1 (en) | 1999-11-18 | 2003-02-18 | Peter L. Hudson | Polynucleotides encoding prostatic growth factor and process for producing prostatic growth factor polypeptides |
| US5994102A (en) | 1994-12-15 | 1999-11-30 | Human Genome Sciences, Inc. | Polynucleotides encoding prostatic growth factor and process for producing prostatic growth factor polypeptides |
| DE69637844D1 (en) | 1995-06-22 | 2009-04-09 | St Vincent S Hospital Sidney L | NEW TGF-BETA-SIMILAR CYTOKIN |
| US6696259B1 (en) | 1995-11-13 | 2004-02-24 | Licentia Ltd. | Assays using glial cell line-derived neurotrophic factor receptors |
| CA2237641A1 (en) | 1995-11-13 | 1997-05-22 | Urmas Arumae | Glial cell line-derived neurotrophic factor receptors |
| US6524802B1 (en) | 1996-03-29 | 2003-02-25 | The Johns Hopkins University School Of Medicine | Methods of detecting growth differentiation factor-14 |
| NZ334592A (en) | 1996-09-11 | 2000-10-27 | Ortho Mcneil Pharm Inc | Protein growth factor related to TNF-beta and coupled with a toxic moiety for use in treating prostate cancer |
| CA2288944A1 (en) * | 1997-05-06 | 1998-11-12 | Human Genome Sciences, Inc. | Enterococcus faecalis polynucleotides and polypeptides |
| NZ501199A (en) | 1997-05-22 | 2001-12-21 | Carlos F | Glial cell line-derived neurotrophic factor receptors (BDNFR-beta) |
| AU8591198A (en) | 1997-07-31 | 1999-02-22 | Johns Hopkins University School Of Medicine, The | Growth differentiation factor-15 |
| EP1100822A1 (en) | 1998-07-23 | 2001-05-23 | Smithkline Beecham Corporation | Secreted cysteine rich protein-6 (scrp-6) |
| US6905817B1 (en) | 1998-10-01 | 2005-06-14 | Licestia Ltd. | Ret-independent signaling pathway for GDNF |
| WO2000020867A1 (en) | 1998-10-01 | 2000-04-13 | Alexey Vladimirovich Titievsky | A novel ret-independent signaling pathway for gdnf |
| US6465181B2 (en) | 1999-03-25 | 2002-10-15 | Abbott Laboratories | Reagents and methods useful for detecting diseases of the prostate |
| US6974684B2 (en) | 2001-08-08 | 2005-12-13 | Curagen Corporation | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| CA2372119A1 (en) | 1999-05-17 | 2000-11-23 | Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Und Zum Vertrie B Von Pharmaka Mbh | Neuroprotective properties of gdf-15, a novel member of the tgf-.beta. superfamily |
| US6866851B1 (en) | 1999-12-28 | 2005-03-15 | Washington University | GFRα1-RET specific agonists and methods therefor |
| EP1276849A4 (en) | 2000-04-12 | 2004-06-09 | Human Genome Sciences Inc | Albumin fusion proteins |
| ES2300325T3 (en) | 2000-04-20 | 2008-06-16 | St Vincent's Hospital Sydney Limited | DIAGNOSTIC TEST THAT IMPLIES THE CYTOKIN 1 MACROFAGOS INHIBITORY (MC1). |
| WO2002020759A2 (en) | 2000-09-08 | 2002-03-14 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A non-steroidal anti-inflammatory drug activated gene with anti-tumorigenic properties |
| JP2005500815A (en) | 2000-12-29 | 2005-01-13 | キュラジェン コーポレイション | Protein and nucleic acid encoding it |
| TWI329129B (en) | 2001-02-08 | 2010-08-21 | Wyeth Corp | Modified and stabilized gdf propeptides and uses thereof |
| EP1395605B8 (en) | 2001-03-09 | 2014-12-17 | Iterative Therapeutics, Inc. | Polymeric immunoglobulin fusion proteins that target low-affinity fcgamma receptors |
| ES2527471T3 (en) | 2001-05-11 | 2015-01-26 | Amgen Inc. | Peptides and related molecules that bind to TALL-1 |
| GB0115195D0 (en) | 2001-06-21 | 2001-08-15 | Bae Systems Plc | Split-pin drill jig |
| US20030053431A1 (en) | 2001-09-10 | 2003-03-20 | Lila Madour | Method for performing handoff in a radio telecommunications network |
| US20060253913A1 (en) | 2001-12-21 | 2006-11-09 | Yue-Jin Huang | Production of hSA-linked butyrylcholinesterases in transgenic mammals |
| EP2277889B1 (en) | 2001-12-21 | 2014-07-09 | Human Genome Sciences, Inc. | Fusion proteins of albumin and interferon beta |
| US7642242B2 (en) | 2002-03-05 | 2010-01-05 | Genentech, Inc. | PRO34128 polypeptides |
| US20100285016A1 (en) | 2002-03-05 | 2010-11-11 | Genentech, Inc. | PRO34128 nucleic acids |
| US7247446B2 (en) | 2002-03-05 | 2007-07-24 | Genentech, Inc. | PRO34128 nucleic acids |
| US7157235B2 (en) | 2002-06-17 | 2007-01-02 | St. Vincent's Hospital Sydney Limited | Methods of diagnosis, prognosis and treatment of cardiovascular disease |
| US7919084B2 (en) | 2002-06-17 | 2011-04-05 | St. Vincent's Hospital Sydney Limited | Methods of diagnosis, prognosis and treatment of cardiovascular disease |
| CN1241946C (en) | 2002-07-01 | 2006-02-15 | 美国福源集团 | Human serum albumins recombined merge protein having hyperplasia stimulation function to multiple cells |
| WO2004043385A2 (en) | 2002-11-08 | 2004-05-27 | Barnes-Jewish Hospital | Methods and compositions for prostate epithelial cell differentiation |
| US7348004B2 (en) | 2003-05-06 | 2008-03-25 | Syntonix Pharmaceuticals, Inc. | Immunoglobulin chimeric monomer-dimer hybrids |
| EA036531B1 (en) * | 2003-11-05 | 2020-11-19 | Роше Гликарт Аг | Type ii anti-cd20 humanized antibody (variants), pharmaceutical composition comprising these antibody variants, and use thereof |
| CN1241941C (en) | 2003-11-21 | 2006-02-15 | 中国科学院上海生命科学研究院 | Protein for promoting nerve differentiation and resisting cell death, and its coding gene |
| EP2774620A1 (en) | 2004-04-13 | 2014-09-10 | St Vincent's Hospital Sydney Limited | Method for modulating weight loss |
| WO2005113585A2 (en) | 2004-05-20 | 2005-12-01 | Acceleron Pharma Inc. | Modified tgf-beta superfamily polypeptides |
| DK1844337T3 (en) | 2005-01-24 | 2013-09-30 | Pepscan Systems Bv | Binding compounds, immunogenic compounds and peptide mimetics |
| ES2543341T3 (en) | 2005-09-13 | 2015-08-18 | National Research Council Of Canada | Methods and compositions to modulate the activity of tumor cells |
| SI2004683T1 (en) | 2006-03-24 | 2016-09-30 | Biogen Hemophilia Inc. | Pc5 as a factor ix propeptide processing enzyme |
| US8974748B2 (en) | 2007-04-05 | 2015-03-10 | Corning Incorporated | Dual inlet microchannel device and method for using same |
| EP2082645A1 (en) | 2006-04-19 | 2009-07-29 | Genentech, Inc. | Novel gene disruptions, compositions and methods relating thereto |
| US7754689B2 (en) | 2006-06-02 | 2010-07-13 | Wyeth Llc | Finger-1 peptide analogs of the TGF-β superfamily |
| NZ574423A (en) | 2006-07-26 | 2012-04-27 | Pepscan Systems Bv | Immunogenic compounds and protein mimics |
| BRPI0715126B8 (en) | 2006-08-04 | 2021-07-27 | Medizinische Hochschule Hannover | methods for risk assessment of cardiac interventions and gdf-15-based uses |
| BRPI0715989A8 (en) * | 2006-10-19 | 2018-03-13 | Genentech Inc | "heavy chain variable sequence (" vh "), vh chain region, light chain variable (" vl ") sequences, vl chain region, vh chain sequences, nucleic acids, vector, cell, antibodies or antibody fragments, antibodies, method for antibody production, use of an antibody, notch3 binding epitopes, composition and use of the composition " |
| SI2144639T1 (en) | 2007-04-25 | 2013-03-29 | Stem Cells Spin S.A. | New stem cell line and its application |
| BRPI0814465B1 (en) | 2007-07-26 | 2021-11-23 | Novagen Holding Corporation | FUSION PROTEIN, DIMER, METHOD FOR PRODUCING A FUSION PROTEIN, CELL LINEAGE, USES OF A FUSION PROTEIN AND A PHARMACEUTICAL COMPOSITION AND PHARMACEUTICAL COMPOSITION |
| CN101854947A (en) | 2007-08-16 | 2010-10-06 | 圣文森特医院悉尼有限公司 | Be used to regulate active medicament of macrophage inhibition factor (MIC-1) and method |
| EP2209486A1 (en) | 2007-10-09 | 2010-07-28 | St Vincent's Hospital Sydney Limited | A method of treating cachexia with the removal or inactivation of macrophage inhibitory cytokine-1 |
| CA2701945A1 (en) | 2007-10-22 | 2009-04-30 | Samuel Norbert Breit | Methods of prognosis of overall survival using mic-1 |
| PT2235064E (en) | 2008-01-07 | 2016-03-01 | Amgen Inc | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| JP5647899B2 (en) | 2008-01-08 | 2015-01-07 | ラツィオファルム ゲーエムベーハーｒａｔｉｏｐｈａｒｍ ＧｍｂＨ | Glycoconjugation of polypeptides using oligosaccharyltransferase |
| JP2011509403A (en) | 2008-01-08 | 2011-03-24 | エフ．ホフマン−ラ ロシュ アーゲー | Means and method for assessing the risk of a patient visiting an emergency room based on GDF-15 |
| WO2009126709A1 (en) | 2008-04-09 | 2009-10-15 | Transtech Pharma, Inc. | Ligands for the glp-1 receptor and methods for discovery thereof |
| EP2279419A1 (en) | 2008-05-20 | 2011-02-02 | Roche Diagnostics GmbH | Gdf-15 as biomarker in type 1 diabetes |
| WO2010007041A1 (en) | 2008-07-14 | 2010-01-21 | Roche Diagnostics Gmbh | Multimarker panel for diagnosing, monitoring and selecting the therapy for patients with heart failure |
| WO2010019263A2 (en) | 2008-08-15 | 2010-02-18 | Genzyme Corporation | Soluble flt constructs for treating cancers |
| WO2010048670A1 (en) | 2008-10-31 | 2010-05-06 | St Vincent's Hospital Sydney Limited | Method of prognosis in chronic kidney disease |
| EP2350265B1 (en) | 2008-10-31 | 2019-04-17 | Janssen Biotech, Inc. | Differentiation of human embryonic stem cells to the pancreatic endocrine lineage |
| EP2211182A1 (en) | 2009-01-16 | 2010-07-28 | Roche Diagnostics GmbH | Method for the assessment of severity of liver cirrhosis |
| EP2209003A1 (en) | 2009-01-16 | 2010-07-21 | F. Hoffmann-Roche AG | Means and methods for differentiating between fibrosis and cirrhosis |
| CA2752157A1 (en) | 2009-02-12 | 2010-08-19 | Stryker Corporation | Peripheral administration of proteins including tgf-.beta. superfamily members for systemic treatment of disorders and disease |
| GB0902737D0 (en) | 2009-02-19 | 2009-04-01 | Univ Gent | GDF15 as a differential marker for spondyloarthropathy |
| CA2752647A1 (en) | 2009-02-24 | 2010-09-02 | The Salk Institute For Biological Studies | Designer ligands of tgf-beta superfamily |
| HRP20240135T1 (en) | 2009-05-05 | 2024-04-12 | Amgen Inc. | Fgf21 mutants and uses thereof |
| WO2011005621A1 (en) | 2009-07-08 | 2011-01-13 | Amgen Inc. | Design of stable and aggregation free antibody fc molecules through ch3 domain interface engineering |
| US20130323835A1 (en) | 2009-07-15 | 2013-12-05 | Zirus, Inc. | Mammalian Genes Involved in Infection |
| US20120309697A1 (en) | 2009-10-28 | 2012-12-06 | Samuel Norbert Breit | Methods of diagnosing and prognosing colonic polyps |
| RU2585488C2 (en) | 2009-11-05 | 2016-05-27 | Дженентек, Инк. | Methods and composition for secretion of heterologous polypeptides |
| WO2011064758A2 (en) | 2009-11-30 | 2011-06-03 | Pfizer Limited | Fusion protein |
| WO2011105573A1 (en) * | 2010-02-26 | 2011-09-01 | 株式会社未来創薬研究所 | Anti-icam3 antibody and use thereof |
| US9212221B2 (en) | 2010-03-03 | 2015-12-15 | Detroit R & D, Inc. | Form-specific antibodies for NAG-1 (MIC-1, GDF-15), H6D and other TGF-β subfamily and heart disease and cancer diagnoses |
| JP5791335B2 (en) | 2010-04-07 | 2015-10-07 | 花王株式会社 | Method for producing organopolysiloxane compound |
| WO2011127458A2 (en) | 2010-04-09 | 2011-10-13 | University Of Southern California | Systems and methods of cell activated, controlled release delivery of growth factors for tissue repair and regeneration |
| EP2383571A1 (en) | 2010-05-02 | 2011-11-02 | Prof. Hess Medical Consulting GmbH | Growth differntioation factor 15 (GDF 15) for risk prediction of diabetic foot ulcer |
| EP2796874B1 (en) | 2010-08-26 | 2017-03-08 | Roche Diagnostics GmbH | Use of biomarkers in monitoring a medication in a subject suffering from heart failure |
| WO2012047427A2 (en) | 2010-08-31 | 2012-04-12 | The Regents Of The University Of California | Antibodies for botulinum neurotoxins |
| EP2439535A1 (en) | 2010-10-07 | 2012-04-11 | F. Hoffmann-La Roche AG | Diagnosis of diabetes related heart disease and GDF-15 and Troponin as predictors for the development of type 2 diabetes mellitus |
| CN103533951B (en) | 2011-04-08 | 2017-04-19 | 安姆根有限公司 | Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (GDF-15) |
| HUE033008T2 (en) | 2011-04-13 | 2017-11-28 | Bristol Myers Squibb Co | Fc fusion proteins comprising novel linkers or arrangements |
| BR112013032630B1 (en) | 2011-06-30 | 2022-06-14 | Chugai Seiyaku Kabushiki Kaisha | HETERODIMERIZED POLYPEPTIDE COMPRISING IGG FC REGION |
| WO2013003680A1 (en) | 2011-06-30 | 2013-01-03 | Genentech, Inc. | Anti-c-met antibody formulations |
| WO2013012648A1 (en) | 2011-07-15 | 2013-01-24 | Emory University | Gdf15 in diagnostic and therapeutic applications |
| US9714276B2 (en) | 2012-01-26 | 2017-07-25 | Amgen Inc. | Growth differentiation factor 15 (GDF-15) polypeptides |
| WO2013148117A1 (en) | 2012-03-27 | 2013-10-03 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
| ES2784223T3 (en) | 2012-06-20 | 2020-09-23 | Univ Virginia Patent Foundation | Compositions and procedures for regulating glucose homeostasis and insulin action |
| WO2014000042A1 (en) | 2012-06-27 | 2014-01-03 | Prince Henry's Institute Of Medical Research | COMPOSITIONS AND METHODS FOR MODIFYING TGF-β FAMILY LIGANDS |
| WO2014011955A2 (en) * | 2012-07-12 | 2014-01-16 | Abbvie, Inc. | Il-1 binding proteins |
| CA2928851A1 (en) * | 2012-07-19 | 2014-01-23 | Alethia Biotherapeutics Inc. | Anti-siglec-15 antibodies |
| BR112015002085A2 (en) | 2012-08-08 | 2017-12-19 | Roche Glycart Ag | protein, polynucleotide, vector, host cell, method for producing protein, pharmaceutical composition, protein use, method of treatment and invention |
| JO3462B1 (en) * | 2012-08-22 | 2020-07-05 | Regeneron Pharma | Human Antibodies to GFR?3 and methods of use thereof |
| WO2014049087A1 (en) | 2012-09-26 | 2014-04-03 | Julius-Maximilians-Universität Würzburg | Monoclonal antibodies to growth and differentiation factor 15 (gdf-15) |
| EP2912064B1 (en) * | 2012-10-24 | 2019-04-24 | Research Development Foundation | Jam-c antibodies and methods for treatment of cancer |
| US20150376294A1 (en) * | 2012-12-03 | 2015-12-31 | Rigshospitalet | Anti-pad2 antibodies and treatment of autoimmune diseases |
| DK2934584T3 (en) * | 2012-12-21 | 2020-05-18 | Aveo Pharmaceuticals Inc | ANTI-GDF15 ANTIBODIES |
| DE102013100322A1 (en) | 2013-01-14 | 2014-07-17 | Claas Selbstfahrende Erntemaschinen Gmbh | cutting |
| EP2950807B1 (en) | 2013-01-30 | 2018-03-28 | NGM Biopharmaceuticals, Inc. | Compositions and methods of use in treating metabolic disorders |
| US9161966B2 (en) | 2013-01-30 | 2015-10-20 | Ngm Biopharmaceuticals, Inc. | GDF15 mutein polypeptides |
| TR201809571T4 (en) | 2013-03-15 | 2018-07-23 | Hoffmann La Roche | IL-22 polypeptides and IL-22 fc fusion proteins and methods of use. |
| WO2014140374A2 (en) * | 2013-03-15 | 2014-09-18 | Novo Nordisk A/S | Monovalent cd27 antibodies |
| MX2015016978A (en) | 2013-06-10 | 2016-04-25 | Merck Sharp & Dohme | Cmv neutralizing antigen binding proteins. |
| EA202092386A1 (en) | 2013-07-31 | 2021-04-30 | Эмджен Инк. | CONSTRUCTIONS BASED ON DIFFERENTIATION AND GROWTH FACTOR 15 (GDF15) |
| CN106687483B (en) | 2014-07-21 | 2020-12-04 | 诺华股份有限公司 | Treatment of cancer using humanized anti-BCMA chimeric antigen receptors |
| KR20170065026A (en) | 2014-07-30 | 2017-06-12 | 엔지엠 바이오파마슈티컬스, 아이엔씨. | Compositions and methods of use for treating metabolic disorders |
| CA2961587A1 (en) | 2014-10-31 | 2016-05-06 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
| GB201512733D0 (en) | 2015-07-20 | 2015-08-26 | Genagon Therapeutics Ab | Therapeutic agents for treating conditions associated with elevated GDF15 |
| US11105818B2 (en) | 2016-01-15 | 2021-08-31 | Novo Nordisk A/S | MIC-1 receptor and uses thereof |
| CN108697795A (en) | 2016-02-29 | 2018-10-23 | 伊莱利利公司 | Gfral receptor therapies |
| EP3423097A4 (en) * | 2016-03-04 | 2019-08-21 | NGM Biopharmaceuticals, Inc. | Compositions and methods for modulating body weight |
| TWI815793B (en) * | 2016-03-31 | 2023-09-21 | 美商恩格姆生物製藥公司 | Binding proteins and methods of use thereof |
| US20190234935A1 (en) | 2016-10-12 | 2019-08-01 | Janssen Biotech, Inc. | Methods for screening for modulators of gdf15-like biological activity |
-
2017
- 2017-03-03 TW TW106107129A patent/TWI815793B/en active
- 2017-03-03 AU AU2017241161A patent/AU2017241161B2/en active Active
- 2017-03-03 SG SG11201807279QA patent/SG11201807279QA/en unknown
- 2017-03-03 CN CN201780030436.7A patent/CN109715206B/en active Active
- 2017-03-03 JP JP2018548669A patent/JP7021099B2/en active Active
- 2017-03-03 PE PE2018001850A patent/PE20190126A1/en unknown
- 2017-03-03 EP EP17776245.7A patent/EP3436068A4/en active Pending
- 2017-03-03 MX MX2018011503A patent/MX2018011503A/en unknown
- 2017-03-03 US US15/449,839 patent/US10174119B2/en active Active
- 2017-03-03 WO PCT/US2017/020654 patent/WO2017172260A1/en active Application Filing
- 2017-03-03 MY MYPI2018703041A patent/MY194669A/en unknown
- 2017-03-03 KR KR1020187030069A patent/KR102370762B1/en active IP Right Grant
- 2017-03-03 CA CA3016035A patent/CA3016035A1/en active Pending
- 2017-03-03 KR KR1020227006994A patent/KR102630655B1/en active IP Right Grant
- 2017-03-03 BR BR112018068898A patent/BR112018068898A2/en unknown
- 2017-03-03 NZ NZ745635A patent/NZ745635A/en unknown
-
2018
- 2018-09-04 PH PH12018501882A patent/PH12018501882A1/en unknown
- 2018-09-06 IL IL261666A patent/IL261666A/en unknown
- 2018-09-12 US US16/129,438 patent/US10975154B2/en active Active
- 2018-09-21 CL CL2018002687A patent/CL2018002687A1/en unknown
- 2018-09-21 CO CONC2018/0009995A patent/CO2018009995A2/en unknown
-
2021
- 2021-03-05 US US17/194,144 patent/US20220073627A1/en active Pending
-
2022
- 2022-02-03 JP JP2022015851A patent/JP2022088355A/en active Pending
- 2022-08-31 AU AU2022224794A patent/AU2022224794A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201807279QA (en) | Binding proteins and methods of use thereof | |
| SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
| SG11201901126UA (en) | Combination therapy for cancer | |
| SG11201810933QA (en) | Anti-c5 antibodies and uses thereof | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201907427YA (en) | Engineered transferrin receptor binding polypeptides | |
| SG11201810420YA (en) | Antibodies to alpha-synuclein and uses thereof | |
| SG11201908280SA (en) | "chimeric molecules and uses thereof" | |
| SG11201806496SA (en) | Antigen binding proteins that bind pd-l1 | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201909963YA (en) | Methods for treating dravet syndrome | |
| SG11201803703UA (en) | Anti-complement factor c1q fab fragments and uses thereof | |
| SG11201804673WA (en) | Novel anti-claudin antibodies and methods of use | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201407486PA (en) | Compositions and methods for modulating utrn expression | |
| SG11201907889YA (en) | Glycan-interacting compounds and methods of use | |
| SG11201908238SA (en) | Anti-c5 antibodies and uses thereof | |
| SG11201906682YA (en) | Glucagon receptor binding proteins and methods of use thereof | |
| SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
| SG11201908326YA (en) | Methods of treating neurodegenerative diseases | |
| SG11201901597UA (en) | Macrophage stimulating protein receptor (or ron - recepteur d' origine nantais) antibodies and uses thereof | |
| SG11201908456VA (en) | Linker units and molecular constructs comprising same | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201903012RA (en) | Anti-c1s antibodies and methods of use thereof |